Dimethandrolone buciclate

Dimethandrolone buciclate (also known as 7α,11β-dimethyl-19-nortestosterone 17β-buciclate or DMAU) is a synthetic and injectable anabolic–androgenic steroid (AAS) and a derivative of nandrolone which is currently under development for potential use as a long-acting male contraceptive and treatment for hypogonadism.

Pharmacology

Dimethandrolone buciclate is a prodrug of dimethandrolone (DMA), which is a potent agonist of the androgen receptor and the progesterone receptor with weaker activity at the estrogen receptor. The drug has a very long duration of action when given by intramuscular injection, with a single dose having been found to suppress gonadotropin levels for up to 12 weeks in clinical studies.

Clinical studies

Clinical studies of dimethandrolone buciclate have been conducted in men. The drug has been found to produce dose-dependent suppression of spermatogenesis and to be well-tolerated. It is currently in phase II clinical trials for use as a male contraceptive.

Potential applications

In addition to potential use as a male contraceptive, dimethandrolone buciclate may also be useful for the treatment of hypogonadism, muscle wasting associated with cachexia, and osteoporosis, among other indications.

See also

• List of androgen esters
• List of progestogen esters

• 
  Dimethandrolone buciclate